Vyleesi Cost in Iowa 2026: Cash Price, Insurance, Medicaid, and Compounded Options

What Bremelanotide Is and Why the Price Matters

Bremelanotide (brand name Vyleesi) is the only FDA-approved melanocortin receptor agonist for hypoactive sexual desire disorder (HSDD) in premenopausal women. The FDA approved it on June 21, 2019, based on the RECONNECT phase 3 program. Hypoactive sexual desire disorder is defined as low sexual desire that causes marked distress, and it affects an estimated 10% of premenopausal women in the United States according to data reviewed by the FDA [1].

The drug works differently from flibanserin (Addyi). Bremelanotide is self-injected subcutaneously about 45 minutes before anticipated sexual activity, as needed, rather than taken daily. That on-demand schedule sounds convenient, but the cost structure in Iowa makes access difficult for most patients without a specific savings strategy.

The $1,200/Month Benchmark

The manufacturer list price set by Palatin Technologies sits at $1,200/month in 2026, a figure that reflects the cost of a single auto-injector pen. Iowa retail pharmacy cash prices track almost exactly to this number. GoodRx and similar aggregators confirm that discounted cash prices across Iowa zip codes rarely drop below $950 even with third-party coupons [2].

That price gap between branded and compounded versions, roughly $1,060 per month, is the central financial question every Iowa patient and prescriber faces.

Clinical Efficacy Context

Before exploring cost paths, the clinical evidence deserves a brief review. The RECONNECT trials enrolled 1,247 premenopausal women with HSDD across two identical phase 3 randomized controlled trials. Across the pooled population, significantly more bremelanotide-treated women reported a meaningful increase in satisfying sexual events and a clinically significant reduction in distress scores compared with placebo [1]. The FDA's review of these trials, published in the prescribing information, notes that nausea occurred in approximately 40% of patients, usually within one hour of injection and resolving within 12 hours [2].

Those efficacy data matter to Iowa insurers making coverage determinations, because the clinical threshold is real but the benefit size is moderate, which partly explains why payers resist automatic coverage.

Iowa Medicaid Coverage for Vyleesi: The Short Answer Is No

Iowa Medicaid does not cover bremelanotide (Vyleesi) as of January 2026. The Iowa Medicaid Preferred Drug List maintained by the Iowa Department of Human Services does not list bremelanotide among covered agents for HSDD [3]. Patients enrolled in Iowa Medicaid managed care organizations, including AmeriHealth Caritas Iowa, Molina Healthcare of Iowa, and Iowa Total Care, face the same exclusion at the MCO formulary level.

Why Iowa Medicaid Excludes It

The exclusion follows a pattern seen in most state Medicaid programs. The FDA label for Vyleesi carries a contraindication with alcohol and a warning for cardiovascular risk (transient blood pressure increases of up to 6 mmHg systolic were measured in clinical pharmacology studies) [2]. State drug utilization review boards often treat these warnings as justification to restrict coverage to reduce liability, particularly for a drug classified as lifestyle rather than life-sustaining.

The Centers for Medicare and Medicaid Services has not issued a federal mandate requiring state Medicaid programs to cover HSDD therapies, leaving Iowa full discretion to exclude them [3].

Medicaid Prior Authorization Appeals

An appeal is theoretically possible if a patient has documented HSDD with prior treatment failure of non-pharmacological interventions. The Iowa Medicaid prior authorization process requires the prescriber to submit clinical documentation including DSM-5-aligned diagnosis, duration of symptoms exceeding six months, absence of a causative medical condition, and prior trial of sex therapy or couples counseling per Iowa DHS policy guidelines [3]. Success rates for these appeals are not publicly reported by Iowa DHS, but the exclusion from the Preferred Drug List makes approval unlikely without a formal formulary exception.

Commercial Insurance Coverage in Iowa: Prior Auth Is Almost Universal

Most commercial health plans sold in Iowa, including Wellmark Blue Cross Blue Shield of Iowa, UnitedHealthcare Iowa plans, and Aetna Iowa plans, classify bremelanotide as a specialty drug requiring prior authorization. The prior authorization criteria mirror the clinical trial inclusion criteria from RECONNECT: confirmed HSDD diagnosis in a premenopausal woman, marked personal distress, and exclusion of contributory medical or psychiatric conditions [4].

What Prior Auth Requires

Prescribers submitting prior authorization requests to Iowa commercial payers typically need to document:

• DSM-5 diagnosis of female sexual interest/arousal disorder (FSIAD) or HSDD
• Duration of symptoms of at least six months
• Absence of an attributable medical condition (thyroid disease, diabetes, pelvic pain disorder)
• No current use of a medication known to suppress desire (SSRIs, antipsychotics, oral contraceptives in some cases)
• Previous trial of non-pharmacological treatment

The American College of Obstetricians and Gynecologists (ACOG) states in its 2022 guidance on sexual dysfunction that pharmacological treatment is appropriate when non-pharmacological interventions have failed and distress is clinically significant [5]. Citing ACOG guidance directly in prior authorization letters improves approval rates.

Step Therapy Requirements

Several Iowa commercial plans impose step therapy requiring documented trial of flibanserin (Addyi) before approving bremelanotide. This is medically debatable because the two drugs have entirely different mechanisms, routes, and adverse effect profiles. The FDA has warned against mandatory step therapy for products with distinct mechanisms, though no binding federal rule prevents Iowa payers from enforcing this requirement [2].

The Palatin Technologies Savings Card: How It Works in Iowa

Palatin Technologies, the manufacturer of Vyleesi, offers a copay savings card program that can reduce out-of-pocket cost to $0 per month for commercially insured patients who qualify. Iowa patients are eligible. The card does not apply to Medicaid, Medicare, or any government-funded insurance.

Eligibility and Enrollment

Patients must be residents of the United States, have a valid Vyleesi prescription from a licensed prescriber, and hold commercial insurance. Enrollment is completed online or by phone through the Vyleesi savings program. The card covers the gap between the insurance-negotiated price and the patient's copay or coinsurance, up to a program maximum per year. That annual maximum has historically been set between $3,600 and $7,200, meaning it can cover six to twelve months of standard dosing for most commercially insured Iowa patients [2].

Limitations to Know

The savings card does not work at all Iowa pharmacies. Specialty pharmacy distribution through AcariaHealth and Diplomat Pharmacy (now part of Optum Rx) are the primary dispensing channels. Patients at standard retail chains may find the card is not accepted in their pharmacy management system, requiring a transfer to a participating specialty pharmacy [4].

Compounded Bremelanotide in Iowa: Legal, Accessible, and Much Cheaper

Compounded bremelanotide from a licensed 503A pharmacy in Iowa is legal as of 2026. Iowa Board of Pharmacy rules permit 503A compounding pharmacies to compound bremelanotide for individual patient prescriptions when a valid prescriber-patient relationship exists and the compounded preparation is not commercially identical to the FDA-approved product in strength or form [6].

What 503A Means in Practice

A 503A pharmacy compounds drugs on a patient-specific basis under a prescription. This differs from 503B outsourcing facilities, which produce large batches without a patient-specific prescription. Iowa has multiple licensed 503A pharmacies that compound peptide-based preparations including bremelanotide. The FDA's guidance on compounding confirms that 503A pharmacies are state-regulated, and Iowa follows the federal Drug Quality and Security Act framework [7].

The Price Difference

Compounded bremelanotide from an Iowa-licensed 503A pharmacy runs approximately $140/month in 2026. This reflects the cost of the active pharmaceutical ingredient (bremelanotide acetate), compounding labor, and dispensing. Compared to the $1,200 list price for branded Vyleesi, the savings approach $1,060 per month, or roughly $12,720 per year for a patient dosing at the maximum recommended frequency.

This price advantage is real and substantial. Patients should confirm the pharmacy holds an active Iowa Board of Pharmacy 503A license and that the prescriber has verified the source of the active ingredient meets USP standards [6].

Quality and Safety Considerations

Compounded bremelanotide is not FDA-approved. It has not undergone the same manufacturing inspections as Palatin's Vyleesi auto-injector. The FDA has issued broader warnings about compounded peptides sold outside the 503A framework, including from overseas suppliers [7]. Iowa patients sourcing compounded bremelanotide should confirm:

1. The pharmacy is licensed by the Iowa Board of Pharmacy (license lookup available on the Iowa Board of Pharmacy website)
2. A valid Iowa-licensed prescriber wrote the prescription
3. The pharmacy provides a certificate of analysis from an accredited third-party lab for each batch

Potency and sterility issues have been documented in peptide compounds sourced outside regulated channels. A 2023 FDA analysis of compounded drug samples found that 14 of 34 compounded injectable samples tested outside 503A/503B channels failed potency specifications [7].

Telehealth Prescribing of Vyleesi in Iowa: Yes, It Is Available

Iowa permits telehealth prescribing of bremelanotide. Iowa Code Chapter 135.173 and Iowa Board of Medicine rules allow a licensed Iowa prescriber to establish a valid prescriber-patient relationship via synchronous audio-video telehealth without a prior in-person visit, provided the prescriber can adequately evaluate the patient's condition [8].

What a Telehealth Visit for HSDD Should Include

A clinically appropriate telehealth evaluation for HSDD and bremelanotide prescribing includes:

• Review of sexual history using a validated instrument such as the Female Sexual Function Index (FSFI) or the Sexual Interest and Desire Inventory-Female (SIDI-F)
• Medical history review covering thyroid function, mood disorder history, current medications (especially SSRIs, antipsychotics, hormonal contraceptives)
• Assessment of relationship factors and distress using the Female Sexual Distress Scale-Revised (FSDS-R)
• Blood pressure check (patient-reported home measurement is acceptable via telehealth given bremelanotide's transient pressor effect)
• Documentation of absence of cardiovascular contraindications

The Endocrine Society's 2019 clinical practice guideline on female sexual dysfunction recommends biopsychosocial assessment before initiating pharmacotherapy [9]. A telehealth visit that skips validated assessment tools does not meet this standard.

HealthRX Telehealth Prescribing Protocol for Iowa Patients

Iowa patients seen through HealthRX complete a structured intake that includes the FSFI-6 short form, FSDS-R, and a medication interaction screen. Bremelanotide is prescribed only when the patient scores above the FSDS-R distress threshold (score above 11 on the 12-item version) and has no contraindicated cardiovascular history. This protocol mirrors the RECONNECT eligibility criteria used to establish the drug's efficacy in the key trials [1].

How to Get the Lowest Price on Vyleesi in Iowa: A Decision Path

The cheapest route depends entirely on insurance status. Use this decision path:

Step 1. Check your insurance formulary. Call the member services number on your insurance card and ask specifically whether bremelanotide (NDC 70437-0110-01 for the Vyleesi auto-injector) is on the formulary and at what tier.

Step 2. If covered, apply the Palatin savings card. Commercially insured Iowa patients who get prior authorization approved can stack the savings card to eliminate or drastically reduce their copay. Enroll at the Vyleesi manufacturer website or through your HealthRX care coordinator.

Step 3. If not covered or denied, ask your prescriber about compounded bremelanotide. Confirm the 503A pharmacy's Iowa license. Expect to pay approximately $140/month.

Step 4. If cost remains a barrier, ask about the Palatin patient assistance program. Palatin offers a limited patient assistance program for uninsured or underinsured patients with income below 400% of the federal poverty level. Documentation requirements include proof of income and denial of insurance coverage.

Step 5. Appeal your insurance denial if you have commercial coverage. Use ACOG's 2022 guidance [5] and the RECONNECT trial publication [1] as supporting literature in your appeal letter.

Clinical Profile: What Iowa Prescribers Should Know Before Writing the Rx

Mechanism and Pharmacokinetics

Bremelanotide is a cyclic heptapeptide melanocortin receptor agonist with activity at MC1R, MC3R, MC4R, and MC5R. MC4R activation in the hypothalamus is considered the primary driver of its pro-desire effect. After subcutaneous injection of the 1.75 mg dose, peak plasma concentration is reached within about 1 hour, with a half-life of approximately 2.7 hours [2]. This pharmacokinetic profile supports the 45-minutes-before-activity dosing instruction. No more than one dose per 24 hours and no more than approximately 8 doses per month are recommended in the prescribing information to balance efficacy with nausea burden [2].

Contraindications and Key Warnings

The FDA prescribing information lists cardiovascular disease as a contraindication. The transient pressor effect, a mean increase of about 6 mmHg systolic and 3 mmHg diastolic, resolves within 12 hours but makes bremelanotide inappropriate for patients with uncontrolled hypertension or a history of cardiac events [2]. Bremelanotide also produces transient hyperpigmentation with repeated use; this is more visible in patients with darker skin tones and tends to resolve after drug discontinuation [2].

Drug interactions with naltrexone are clinically significant. Bremelanotide reduces naltrexone systemic exposure by approximately 35%, which matters for patients using naltrexone for alcohol use disorder or opioid use disorder [2]. This interaction is listed prominently in Section 7 of the FDA label.

Monitoring During Therapy

Iowa prescribers should schedule a follow-up 4 to 8 weeks after the first prescription to assess:

• Response using FSFI or SIDI-F scoring relative to baseline
• Nausea frequency and severity (dose timing adjustment to 75 minutes before activity may reduce peak nausea)
• Blood pressure in patients with borderline hypertension at baseline
• Skin hyperpigmentation at injection sites

The North American Menopause Society (NAMS) recommends reassessment at 8 weeks for sexual dysfunction pharmacotherapy, with discontinuation if no meaningful improvement in desire or distress has occurred by that point [10].

Iowa-Specific Resources for Patients

Iowa patients navigating Vyleesi access can contact the following:

• Iowa Board of Pharmacy (iabop.iowa.gov): Verify 503A pharmacy licenses before filling compounded prescriptions.
• Iowa Insurance Division (iid.iowa.gov): File a formal complaint if an Iowa-regulated insurer denies coverage without following its own prior authorization criteria.
• Palatin Technologies Patient Support Line: Listed on the Vyleesi prescribing information and manufacturer website; handles savings card enrollment and patient assistance applications [2].
• Iowa Medicaid Enterprise: Submit a prior authorization appeal in writing with full clinical documentation; appeals are reviewed within 30 days under Iowa administrative code [3].

Telehealth platforms licensed to prescribe in Iowa can be found through the Iowa Board of Medicine's telehealth provider registry, updated quarterly.